Pancreatic Cancer Research

ResearcherCentral South UniversityActive in the last 2 years

Yixiong Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8215-426X; OpenAlex author ID A5073848311. Sources: OpenAlex.

Their work

Papers
15 (first author 3, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
52
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 3 papers

Papers 15

  1. Early onset pancreatic cancer: A review. First author DOI 10.1016/j.tranon.2024.102239↗
  2. Microbiome-metabolome interplay in pancreatic cancer progression: insights from multi-omics analysis. Co-author DOI 10.1186/s12943-025-02458-9↗
  3. Noninvasive Computed Tomography-Based Quantification of Tumor Fibrosis Predicts Pancreatic Cancer Response to Gemcitabine/Nab-Paclitaxel. Co-author DOI 10.34133/research.0937↗
  4. Bioinformatics analysis combined with experiments to explore potential prognostic factors for pancreatic cancer. Last author DOI 10.1186/s12935-020-01474-7↗
  5. [Current consensus and controversy in neoadjuvant therapy for pancreatic cancer]. First author DOI 10.3760/cma.j.issn.0529-5815.2020.02.005↗
  6. HNF1A/CASC2 regulates pancreatic cancer cell proliferation through PTEN/Akt signaling. Co-author DOI 10.1002/jcb.26395↗
  7. Long noncoding RNA FEZF1-AS1 predicts poor prognosis and modulates pancreatic cancer cell proliferation and invasion through miR-142/HIF-1α and miR-133a/EGFR u… Last author DOI 10.1002/jcp.28188↗
  8. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn. Last author DOI 10.1016/j.biopha.2018.06.114↗
  9. Krüppel-like factor 8 induces epithelial-to-mesenchymal transition and promotes invasion of pancreatic cancer cells through transcriptional activation of four … Last author DOI 10.3892/ol.2017.6734↗
  10. KLF8 knockdown triggered growth inhibition and induced cell phase arrest in human pancreatic cancer cells. First author DOI 10.1016/j.gene.2016.03.025↗
  11. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗
  12. Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus … Co-author DOI 10.3892/ijo.2015.3128↗
  13. RNA interference‑mediated inhibition of survivin and VEGF in pancreatic cancer cells in vitro. Last author DOI 10.3892/mmr.2013.1361↗
  14. Clinical utility of the mood and anxiety symptom questionnaire in a chinese sample of patients with pancreatic cancer. Last author DOI 10.1097/sga.0b013e3182572640↗
  15. Lentivirus-mediated shRNA targeting XIAP and survivin inhibit SW1990 pancreatic cancer cell proliferation in vitro and in vivo. Co-author DOI 10.3892/mmr.2011.472↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xuejun Gong · 3 shared papers, 2025 · strength 0.81
  2. Dong Luo · 3 shared papers, 2025 · strength 0.81
  3. Mujing Ke · 3 shared papers, 2018–2020 · strength 0.45
  4. Zhenglin Ou · 3 shared papers, 2018–2020 · strength 0.37
  5. Xiaoping Yi · 3 shared papers, 2016–2025 · strength 0.35
  6. Jun Cheng · 1 shared paper, 2025 · strength 0.19
  7. Yize Mao · 1 shared paper, 2025 · strength 0.19
  8. Lizhi Liu · 1 shared paper, 2025 · strength 0.19
  9. Ningning Niu · 1 shared paper, 2025 · strength 0.19
  10. Peng Luo · 1 shared paper, 2025 · strength 0.19
  11. Qiuxia Yang · 1 shared paper, 2025 · strength 0.19
  12. Wenzheng Li · 2 shared papers, 2016–2017 · strength 0.16
  13. Hongyan Zai · 2 shared papers, 2016–2017 · strength 0.16
  14. Yaqun Yu · 1 shared paper, 2019 · strength 0.11
  15. Weijia Liao · 1 shared paper, 2019 · strength 0.11
  16. Shuai Liang · 1 shared paper, 2019 · strength 0.11
  17. Yebin Lu · 1 shared paper, 2019 · strength 0.11
  18. Min Zhang · 1 shared paper, 2019 · strength 0.11
  19. Zhen Luo · 1 shared paper, 2019 · strength 0.11
  20. Tong Han · 1 shared paper, 2019 · strength 0.11
  21. Neng Tang · 1 shared paper, 2018 · strength 0.10
  22. Guodong Liu · 1 shared paper, 2018 · strength 0.10
  23. Quanxing Ni · 2 shared papers, 2015–2016 · strength 0.08
  24. Bei Sun · 2 shared papers, 2015–2016 · strength 0.08
  25. Jiangtao Li · 2 shared papers, 2015–2016 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.